CANbridge to develop and commercialize Apogenix’s APG101 in glioblastoma for China
APG101 is a fully-human fusion protein that inhibits the CD95 ligand, a member of the tumor necrosis factor (TNF) family. It isindicated to treat glioblastoma multiforme in China,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.